Erratum: Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain (Lupus (2008) 17 (849-859) DOI: 10.1177/0961203308093554);Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain

Lupus

Volumn 17, Issue 9, 2008, Pages 849-859

  Sabio, José Mario ^a   Zamora Pasadas, M ^a   Jimenez Jaimez J ^a   Albadalejo, F ^b   Vargas Hitos, J ^a   Rodriguez del Aguila M D M ^a   Hidalgo Tenorio, C ^a   Gonzalez Gay, M A ^b   Alonso, J J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

Author keywords

Cardiovascular risk factors; Metabolic syndrome; Systemic lupus erythematosus

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE MARKER; EDUCATIONAL STATUS; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPAIN; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; AGE; CASE CONTROL STUDY; COMORBIDITY; GENETICS; MIDDLE AGED;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; PREVALENCE; RISK FACTORS; SPAIN; YOUNG ADULT;

EID: 58949094247     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203308100556     Document Type: Erratum

References (45)

1. Roman MJ Shanker BA Davis A. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
2. Asanuma Y Oeser A Shintani AK. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-2415.
3. Esdaile JM Abrahamowicz M Grodzicky T. Traditional Framingham risk factors fall to account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.
4. Selzer F Sutton-Tyrrell K Fitzgerald SG. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 151-159.
5. Sabio JM Mediavilla JD Fernández-Torres C Aliaga L Jiménez-Alonso J. Lupus 2001; 10: 451 [letter].
6. Grundy SM Brewer HB Cleeman JI Smith SC Lenfant C. American Heart Association. National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
7. Bonora E Kiechl S Willeit J. Bruneck study. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: Prospective data from the Bruneck study. Diabetes Care 2003; 26: 1251-1257.
8. Iglseder B Cip P Malaimare L Ladurner G Paulweber B. The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men. Stroke 2005; 36: 1212-1217.
9. Sundström J Riserus U Byberg L Zethelius B Lithell H Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: Prospective, population based cohort study. BMJ 2006; 332: 878-882.
10. Ford ES Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575-581.
11. Magadmi ME Ahmad Y Turkie W. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006; 33: 50-56.
12. Chung CP Avalos I Oeser A. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-214.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 (Suppl. 1): S43-S48.
17. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610.
18. Bombardier C Gladman DD Urowitz MB Caron D Chang CH. Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
19. Gladman D Ginzler E Goldsmith C. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
20. Jialal I Stein D Balis D Grundy SM Adams-Huet B Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935.
21. Colquhoun D Keech A Hunt D. LIPID Study Investigators. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: Results from the LIPID study. Eur Heart J 2004; 25: 771-777.
22. Jonkers IJ Mohrschladt MF Westendorp RG van der Laarse A Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: Reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002; 112: 275-280.
23. Ilowite NT Samuel P Ginzler E Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31: 859-863.
24. Patel DA Srinivasan SR Xu JH Chen W Berenson GS. Adiponectin and its correlates of cardiovascular risk in young adults: The Bogalusa Heart Study. Metabolism 2006; 55: 1551-1557.
25. Albert MA Glynn RJ Buring J Ridker PM. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006; 114: 2619-2626.
26. Ford ES Kohl HW Mokdad AH Ajani UA. Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obes Res 2005; 13: 608-614.
27. Van Oostrom AJ Alipour A Plokker TW Sniderman AD Cabezas MC. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 2006; 190: 167-173.
28. Ajjan R Grant PJ Futers TS. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 2005; 94: 1048-1053.
29. Manger K Kusus M Forster C. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003; 62: 846-850.
30. Selzer F Sutton-Tyrrell K Fitzgerald S Tracy R Kuller L Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001; 37: 1075-1082.
31. Maksimowicz-McKinnon K Magder LS Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006; 33: 2458-2463.
32. Onat A Uyarel H Hergenc G. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 2006; 19: 1055-1062.
33. Culleton BF Larson MG Kannel WB Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
34. Fessler BJ Alarcon GS McGwin G. LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473-1480.
35. Ruiz-Irastorza G Egurbide MV Pijoan JI. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577-583.
36. Petri M. Hydroxychloroquine used in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis. Lupus 1996; 5 (Suppl. 1): S16-S22.
37. Rahman P Gladman DD Urowitz MB Yuen K Hallett D Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26: 325-330.
38. Wallace DJ Metzger AL Stecher VJ Turnbull BA Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-326.
39. Hodis HN Quismorio FP Wickham E Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 661-665.
40. Borba EF Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 780-785.
41. Wei L MacDonald TM Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770.
42. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 2379-2380.
43. Da Silva JA Jacobs JW Kirwan JR. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-293.
44. Petri M Lakatta C Magder L Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med 1994; 96: 254-259.
45. Zonana-Nacach A Barr SG Magder LS Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.